Glioblastoma Multiforme Clinical Trial
Official title:
A Phase I Study of Dietary Methionine Restriction and Temodar® (Temozolomide) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme
Objectives:
1. To determine the safety, tolerability and efficacy of dietary methionine restriction
for 7 days alternating with Temodar® (Temozolomide) given once a day for seven days and
this repeated for up to one year in the treatment of patients with recurrent and/or
progressive glioblastoma.
2. To determine the short- and long-term toxicity of dietary methionine restriction
combined with Temodar® in glioblastoma patients.
3. To measure and correlate patients' tumor responses and progression-free survival with:
serum methionine and peripheral blood lymphocyte methylation levels. In any patient
undergoing surgery, to measure tumor alkylguanyl transferase (AGT) and methionine
levels and compare to control specimens.
Methionine is an essential amino acid. Many solid tumors depend on the methionine that is
taken in through the diet. The tumors need methionine to grow. A methionine free (or
reduced) diet may help to shrink or slow the growth of some tumors. Temozolomide is a drug
that is commonly used in the treatment of glioma. A methionine free (or reduced) diet may
increase the effectiveness of temozolomide in the treatment of glioma.
Before treatment, you will have a complete physical exam and blood (around 2 tablespoons)
will be collected for routine tests. You will have either a magnetic resonance imaging (MRI)
scan or a computed tomography (CT) scan of the brain. Women who are able to have children
must have a negative blood pregnancy test. You will then meet with a study dietician. The
dietician will give you written instructions and make a food plan based on your needs. The
instructions and food plan will help you maintain a methionine-free (or reduced) diet during
the study.
During the study, all participants will receive standard chemotherapy with temozolomide by
mouth once a day at bedtime for 7 days on Days 8 through 14 and 22 through 28, every 28
days, 4 weeks This 4-week period is called a cycle of chemotherapy. This 4 week cycle will
be repeated as long as the disease does not get worse.
During treatment, you will be asked to maintain a methionine free diet during Days 1 - 7 and
Days 15 - 21. During the periods of methionine free diet, you will consume only "shakes"
containing Hominex-2®. The Hominex-2® shakes are nutritionally complete and easy to prepare.
You will be given instructions on how to maintain this methionine-free diet.
All participants enrolled in the study will consume a methionine free diet for 1 week,
alternating with temozolomide chemotherapy for 1 week. The participants will then be
switched to a methionine "replete" diet for 1 week while taking chemotherapy. This diet and
chemotherapy schedule will be continued for as long as the treatment is effective and
tolerable. This replete diet contains methionine. The dietician will record what you eat to
make sure you are eating the right amount of methionine during this period. This 4-week
schedule will be repeated as long as you are on the study.
If you experience any intolerable side effects or the disease gets worse, you will be taken
off the study and your doctor will discuss other treatment options with you.
During treatment, you will have blood (around 1 tablespoon) collected every 2 weeks for
routine tests. Every 4 weeks for the first 16 weeks then every 8 weeks for the rest of the
study, you will have check up visits. At these visits, you will have a complete physical
exam and have blood collected (around 1 tablespoon) for routine tests. You will also have a
dietary consultation. Every 8 weeks during the study, you will have either a MRI scan or a
CT scan of the brain. If your doctor feels it is necessary, the tests may be done more often
or you may have other tests as needed for your care.
This is an investigational study. Methionine restriction diet (Hominex®-2 Amino
Acid-Modified Medical Food) has been approved by the FDA for nutrition support of children
and adults with vitamin B6-nonresponsive homocystinuria. However, its use in this study is
investigational. Temozolomide has been approved by the FDA for the treatment of brain tumors
and is commercially available. The use of this combination is experimental. Forty-four
participants will take part in this study.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05023551 -
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
|
Early Phase 1 | |
Recruiting |
NCT06059690 -
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116411 -
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
|
Phase 2 | |
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00038493 -
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
Recruiting |
NCT01923922 -
CT Perfusion in the Prognostication of Cerebral High Grade Glioma
|
N/A | |
Completed |
NCT01956734 -
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
|
Phase 1 | |
Completed |
NCT01402063 -
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
|
Phase 2 | |
Completed |
NCT01301430 -
Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.
|
Phase 1/Phase 2 | |
Suspended |
NCT01386710 -
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Terminated |
NCT00990496 -
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
|
Phase 1 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Recruiting |
NCT05366179 -
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
|
Phase 1 |